Form 4: Spyre Therapeutics Director Stelzer Acquires Stock Options
SEC Form 4 Filing
Director Laurie Stelzer acquired stock options for 11,323 shares of Spyre Therapeutics common stock on May 14, 2024.
Summary
- On May 14, 2024, Laurie Stelzer, a director of Spyre Therapeutics, Inc. (SYRE), acquired stock options representing the right to purchase 11,323 shares of the company's common stock.
- The exercise price of these options is $39.29 per share.
- The options vest in 12 equal monthly installments starting May 14, 2024, and expire on May 14, 2034, contingent upon continuous service with the Issuer.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a standard insider transaction. The acquisition of stock options can be seen as a positive sign, but it's a routine event.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency regarding insider transactions, allowing investors to monitor the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director can positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of the stock option grant. |
| 05/14/2024 | Vesting start date for the stock options. |
| 05/14/2034 | Expiration date of the stock options. |
| 05/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.